<code id='22E59716FF'></code><style id='22E59716FF'></style>
    • <acronym id='22E59716FF'></acronym>
      <center id='22E59716FF'><center id='22E59716FF'><tfoot id='22E59716FF'></tfoot></center><abbr id='22E59716FF'><dir id='22E59716FF'><tfoot id='22E59716FF'></tfoot><noframes id='22E59716FF'>

    • <optgroup id='22E59716FF'><strike id='22E59716FF'><sup id='22E59716FF'></sup></strike><code id='22E59716FF'></code></optgroup>
        1. <b id='22E59716FF'><label id='22E59716FF'><select id='22E59716FF'><dt id='22E59716FF'><span id='22E59716FF'></span></dt></select></label></b><u id='22E59716FF'></u>
          <i id='22E59716FF'><strike id='22E59716FF'><tt id='22E59716FF'><pre id='22E59716FF'></pre></tt></strike></i>

          
          WSS
          King Street Properties’ Pathway Devens campus. -- biotech coverage from STAT
          Pat Greenhouse/Globe Staff

          MORRISVILLE, N.C. — Ten minutes from the Raleigh airport, the future of biotech is under construction.

          On either side of a new stretch of four-lane highway sit two $1 billion biomanufacturing campuses, which will bring a combined 2.5 million square feet of research and development and advanced manufacturing space to a region that has become the No. 1 place where North America makes prescription drugs.

          advertisement

          One campus, called Pathway Triangle, is being built by a developer from Boston, King Street Properties. King Street — which has projects in Cambridge, Waltham, Allston, and Lexington — is building a similarly vast biomanufacturing campus in Devens. But these days it also sees a land of opportunity 700 miles to the south, in North Carolina.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment